Mitchell Steiner

Mitchell Steiner

Company: Veru Inc.

Job title: Chief Executive Officer


Advancing Enobosarm, An Oral Novel Selective Androgen Receptor Modulator (SARM), to Avoid Muscle Loss and Augment Fat Loss When Combined with a Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Drugs for Potentially Higher Quality Weight Loss 9:00 am

Highlighting the concerns that muscle loss caused by GLP-1 receptor agonists may be responsible for weight loss plateau, upon stopping GLP-1 RA, the fat and weight rebound regain, and may accelerate the development of frailty in at-risk older sarcopenic obese patients with potential for physical function limitations Presenting the 5 clinical studies of enobosarm in…Read more

day: Conference Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.